|
Ridogrel
resources
DRUG INFO
Ridogrel
Drug Name:
Ridogrel
|
|
|
Indication: Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.
Pharmacology: This drug is used with streptokinase as an adjunctive therapy to reduce the formation and size of blood clots. Blood clots can cause ischemic cardiac events (heart attacks). Ridorgel has the dual property of inhibiting the synthesis of thromboxane and blocking the receptors of thromboxane/prostaglandin/endoperoxides. It has been shown to accelerate the speed of recanalization and to delay or prevent reocclusion during systemic thrombolysis with tissue plasminogen activator (streptokinase).
Mechanism Of Action: Ridogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. It is a more potent antiplatelet agent than aspirin and might offer an advantage over aspirin as an adjunct to thrombolysis in patients suffering from acute myocardial infarction.
Drug Category: Thrombolytic agents
Brand Names/Synonyms: RIDOGREL; Ridogrel [Usan:Ban:Inn]; Ridogrelum [Inn-Latin]
Dosage Forms: TABLETS
Absorption: Rapidly absorbed after oral administration (30-60 min)
Interactions: Not Available
Chemical IUPAC Name: 5-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]-methylidene]aminooxypentanoic acid
Chemical Formula: C18H17F3N2O3
Half Life: 6-9 hours
Drug Type: Approved Drug
# Accession No: APRD00271
CAS Registry Number: 110140-89-1
| | |
